Chromosome 20 trisomy

disease
On this page

Also known as mosaic trisomy 20trisomy 20trisomy 20 mosaicismtrisomy chromosome 20

Summary

Chromosome 20 trisomy (MONDO:0022757) is a disease. A subtype of chromosome 20 disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namechromosome 20 trisomy
Mondo IDMONDO:0022757
MeSHC535372
NCITC36397
UMLSC5979883
MedGen1876538
GARD0005332
Is cancer (heuristic)no

Also known as: mosaic trisomy 20 · trisomy 20 · trisomy 20 mosaicism · trisomy chromosome 20

Data availability: 4 cell lines.

Disease family

An umbrella term covering 1 Mondo subtype.

Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › chromosomal disorder › autosomal anomaly › chromosome 20 disorder › chromosome 20 trisomy

Related subtypes (5): ring chromosome 20, partial deletion of chromosome 20, partial trisomy of chromosome 20, maternal uniparental disomy of chromosome 20, paternal uniparental disomy of chromosome 20

Subtypes (1): mosaic trisomy 20

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.